

This will be done. But at the outset, we wish to make one point clear. The American Medical Association has been serving the public interest since 1847. Throughout these years, and today, the physicians of this country and their professional association have had a single purpose: "To promote the science and art of medicine and the betterment of public health." It is so stated in the Constitution of the American Medical Association. We have no compacts with industry, with any vested interests, or even with Government which can thwart this objective. Our agreement is with our oath, our consciences, and with the patients we serve.

Now to turn to the seven questions.

The first requests information concerning procedures in accepting advertising of drugs.

The Division of Scientific Activities, Dr. Hugh H. Hussey, director, formerly dean of the Georgetown University School of Medicine, is charged with the responsibility for administering the association's advertising principles. The Office of Advertising Evaluation, a department in the Division office, performs the necessary staff functions of the program. It is important to note that administratively the department of Advertising Evaluation is not answerable to the Advertising Department. It is a separate function responsible only to the members of the AMA staff who have the responsibility of directing the association's activities in scientific areas.

Since the American Medical Association established the Journal of the American Medical Association in 1884, advertising copy submitted for publication has been evaluated and required to conform to the association's advertising policies as a prerequisite for publication. Repeatedly since 1870, the House of Delegates has directed that advertising principles govern acceptance of advertising in all AMA scientific publications. As early as 1870, the house requested that no advertisements of drug products be accepted unless the official or chemical name and the formula were inserted as part of the advertisement.

AMA's stated principles of advertising, which you have already supplied for the record? Who makes the final determination whether an advertisement is acceptable, especially when there is a question of its conformity to your stated standards?

2. How many drug company advertisements have been rejected by the Journal of the American Medical Association in the last 5 years? Please supply the names of the products, companies, detailed reasons for rejection, and final disposition.

3. I understand that the AMA receives grants and other contributions from drug firms and their foundations for special purposes. Please tell us how much was received from such sources for the past 15 years? What were these funds used for?

4. The AMA News, dated May 2, 1966, shows the AMA's net worth to be \$14,307,344 as of December 31, 1965. The AMA News for May 13, 1968, shows a net worth of \$19,011,610 as of December 31, 1967. This is about a \$5 million increase in 2 years. Does this reflect profits made in the advertising you carry?

5. Your investment portfolio increased by about \$5 million in a 2-year period. Can you tell us about this? Does your portfolio include any investments directly or indirectly in drug firms? Please give us details.

6. What are the names of AMA personnel who went to industry directly or indirectly and those who have come to the AMA from industry for the last 10 years?

7. Many authorities who have appeared before our committee have expressed concern that the Food and Drug Administration has neither the funds nor the personnel to adequately perform its proper role—i.e., namely, the responsibility of seeing to it that drugs approved for marketing are both efficacious and safe. It goes without saying that some means must be devised by which the public interest is protected. In this regard:

(a) What official steps, if any, has the AMA taken to solve this important problem?

(b) Does AMA have any concrete suggestions as to the manner in which it might work with the FDA in resolving this problem?

(c) In what ways might the AMA assist the FDA in carrying out this crucial function?

As stated in my letter of June 5, we would appreciate receiving 15 copies of your statement by July 25 and 75 copies on the date of your appearance.

Sincerely,

GAYLORD NELSON,
Chairman, Monopoly Subcommittee.